Mitralign Inc., a cardiac device company, announced today it has completed enrollment in a study in Europe investigating its lead device, the Mitralign System, in patients with functional mitral regurgitation (FMR). Pending successful outcomes from the study, the company will seek CE Mark approval in the European Union (EU) as a first step toward commercializing the Mitralign System. Receiving the CE Mark demonstrates that a product has been assessed by the European Commission for Enterprise and Industry and meets EU safety, health and environmental protection requirements.
Achieve3000 continues to garner national recognition for its corporate growth. The leader in online differentiated literacy instruction is listed on the Deloitte 2013 Technology Fast 500™, an annual ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. In addition, earlier this fall, the company earned its sixth listing on the Inc. 5000, honoring the fastest growing private companies in the United States, where it was ranked as one of the top 50 education companies. From 2008-2012, the New Jersey-based education company realized revenue growth of 145 percent.
Since it was founded in 1984, Shoe Sensation has focused on bringing well-known, branded footwear and accessories to residents of small-town America who otherwise would have to drive up to 45 minutes for a simple shoe shopping excursion. The markets may be small, but there is still profit to be made while serving a real need. After all, residents of these small cities have to purchase their footwear from somewhere and Shoe Sensation wants to be their first choice.
Brickell Biotech, Inc. ("Brickell"), a development-stage pharmaceutical company focused on the development of innovative drug therapies for the treatment of skin diseases, today announced a $7 million Series B financing round. Brickell's current pipeline includes new chemical entities in dermatology for indications including acne, atopic dermatitis, and hyperhidrosis.
In January 2021, Palisade Capital Management published a research piece entitled “The Time For Convertibles Is (Still) Now”, where we outlined the advantages of investing in the convertible asset class, both historically and tactically, given an impending, post COVID-19 economic cycle.
In this study, we seek to touch upon and update key aspects of Palisade's unique approach to investing in convertibles. Palisade's convertible strategies emphasize Growth convertibles (as opposed to Value convertibles) and Large- and Mid-Capitalization convertibles (rather than Small-Capitalization convertibles).